Clinical Trials Logo

Glioblastoma Multiforme clinical trials

View clinical trials related to Glioblastoma Multiforme.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05908669 Enrolling by invitation - Clinical trials for Glioblastoma Multiforme

Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme

Start date: August 25, 2023
Phase:
Study type: Observational

This is a feasibility single arm study designed for obtaining early data for optimization and evaluation of the clinical potential for a new MR technique using deuterated glucose. The purpose of the study is to investigate whether this technique is useful in metabolic imaging of glioblastoma multiforme (GBM) and whether radiochemotherapy (RCT) induced changes in the brain metabolism can be detected and might be predictive for treatment response. The study will include 10 patients with histologically verified GBM scheduled for standard RCT. Patients will have MRI scan performed before and within 8 weeks after starting RCT. The scans will include imaging after oral intake of deuterated glucose, so called deuterium metabolic imaging (DMI). Based on this study, the most optimal scanning technique, output variables of highest discriminative power with respect to RCT, and potential predictive markers for response will be selected for further clinical investigation.

NCT ID: NCT03170141 Enrolling by invitation - Clinical trials for Glioblastoma Multiforme

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Start date: May 31, 2020
Phase: Phase 1
Study type: Interventional

This study aims to treat patients who have been diagnosed with brain cancer including glioblastoma multiforme (GBM). The treatment combines two different approaches to fight cancer: immune modulators and antigen-specific T cells. Immune checkpoint antibodies have been tested on various tumors with good outcomes. GBM is known to express increased levels of certain antigens that can be targeted by antigen-specific T cells. Thus, in this study, the gene-modified T cells specific for GBM antigens will be combined with immune modulatory genes to treat patients in dose escalation cohorts.